环丙基甲基酮的合成研究进展

环丙基甲基酮是合成环丙氟哌酸类广谱抗菌药物和抗艾滋特效药依法韦仑的重要中间体,在医药、化工及农林等领域均有广泛应用。环丙基甲基酮的合成方法大致分为4类,分别以酮类、酯类、醇类及呋喃有机物为原料,在一定条件下生成环丙基甲基酮粗品,经萃取及精馏得到环丙基甲基酮纯品。本文综述了环丙基甲基酮的合成研究进展。     

γ-取代丙基环四硅氧烷的合成及其与D_4的乳液共聚反应

本文合成了四种γ-取代丙基环四硅氧烷。通过阳离子型和阴离子型乳液共聚的方法,分别使其与八甲基环四硅氧烷共聚,合成了含有γ-羟丙基、γ-氯丙基和γ-乙酰氧丙基等活性碳官能团有机硅聚合物的稳定乳液;研究了乳液共聚反应过程中的单体转化率、聚合物分子量的变化以及温度、催化剂、乳化剂、取代基团等因素的影响。     

有机硅活性中间体的研究——Ⅳ.光化学方法产生环丙基苯基硅烯及其反应

含有环丙基的硅烯和卡宾具有特殊的反应性能。例如,当环丙基卡宾生成后,会发生重排和碎裂(fragmentation),经过两个独立的协同过程,分別生成环丁烯衍生物和含碳-碳叁键的乙炔衍生物。由此引起了我们研究含环丙基硅烯的兴趣。     

乙二醇-聚(咪唑丙基-天冬酰胺)-聚丙氨酸三嵌段共聚物的合成及其pH-响应性药物控制释放性能的研究

聚天冬氨酸及其衍生物是一种具有良好生物相容性和可生物降解性的高分子材料, 被广泛应用于生物医药领域. 本研究通过大分子引发剂ω-胺基-α-甲氧基聚乙二醇引发N-羧基-α-氨基环内酸酐开环聚合和N-(3-氨丙基)咪唑侧基改性, 制备了一种侧链含有咪唑丙基的聚乙二醇-聚(咪唑丙基-天冬酰胺)-聚丙氨酸三嵌段共聚物. 在水溶液中, 此聚合物可自组装形成一种核-壳-冠型的三层共聚物胶束, 其中疏水性的聚丙氨酸链段自聚集形成胶束的核, 聚(咪唑丙基-天冬酰胺)链段形成具有pH-响应性的壳层, 用于包埋和释放药物, 外围的聚乙二醇链段可以提供一个稳定的水合冠层, 延长药物的体内循环时间. 利用咪唑环与游离阿霉素之间的π-π相互作用和疏水相互作用可以在自组装的过程中将阿霉素包埋到胶束内. 研究发现, 载药胶束随环境pH 值的降低药物的释放速率显著增加. 这主要是由于咪唑环在酸性条件下的质子化导致链段亲疏水性质发生明显变化.     

微量元素铁代谢的研究进展

综述了微量元素铁在人体内的代谢,包括膳食结构及膳食中蛋白质、热 能、锌、钙营养水平对铁代谢的影响,妊娠期间和热环境下的铁代谢以及遗传缺陷疾病与铁代谢的关系研究成果,以期对预防缺物性疾病有进一步的认识。     

bronsted酸性离子液体催化合成阿司匹林

以邻苯二胺和环丙基甲酸为原料,以多聚磷酸(PPA)为催化剂,在微波辐射下合成了环丙基苯并咪唑,用碘甲烷季胺化得到未见文献报道的环丙基苯并咪唑盐,通过苯并咪唑盐与Grignard试剂加成后水解反应制备环丙基甲基酮。经元素分析和红外光谱、质谱、核磁共振测试技术表征确证了结构。环丙基甲基酮为无色液体,合成环丙基甲基酮方法的产率为67%,为环丙基甲基酮提供了一种未见文献报道的合成方法。     

基于药物数据报道数据库的虚拟组合片段库构建

对药物数据报道数据库中142553个药物分子进行统计分析, 提取得到了这些药物分子的共同结构特征. 根据药物分子的结构特征将其拆分为环结构、侧链和连接子, 共整理得到32017个片段结构, 其中环结构13642个、侧链10076个、连接子8299个. 为更好地指导全新药物设计, 利用拆分片段构建了三个虚拟组合片段数据库: 用环结构和侧链组合方式构建了药效基团库, 含有34244个片段; 用环结构的刚性特点构建了基本骨架库, 含有片段13574个; 直接利用连接子构建了连接片段库, 含有连接片段8051个. 库中所有片段都经过能量优化, 均具有合理的构型和构象, 可以用于虚拟组合库的构建和全新药物设计.     

硅杂四元环化合物的合成和反应

硅杂四元环化合物在有机硅化学中是一类非常重要的小分子环系化合物, 广泛应用于有机化学、金属有机化学以及材料化学. 环上只含有一个硅原子的硅杂环丁烷可以通过γ-卤代丙基硅烷的Grignard反应、Si＝C键与烯烃的 [2＋2]环加成反应以及硅杂环丙烷的扩环反应合成, 环上只含有一个硅原子的硅杂环丁烯可以通过格氏试剂或锂试剂参与的Si—C键的关环反应、硅杂环丁烷的转化反应、硅卡宾对C—H键的插入反应、Si＝C键与炔烃的[2＋2]环加成反应以及二炔基硅烷的分子内成环反应等途径合成. 硅杂环丁烷和硅杂环丁烯由于存在环张力和具有一定的Lewis酸性, 能够通过扩环反应生成五元和六元含硅杂环化合物, 也能够通过开环反应生成不同结构的有机硅分子和聚合物, 抑或实现有机反应在温和条件下的转化.     

三氟甲磺酸催化环丙基醇与磺酰胺的串联反应高效合成四氢吡咯衍生物

三氟甲磺酸(Tf OH)可以用于催化取代环丙基醇与磺酰胺经分子间串联合成四氢吡咯衍生物的反应.在100℃以及10 mol%Tf OH作为催化剂作用下,可获得产率为16%~83%的四氢吡咯衍生物目标产物.该反应在优化条件下能够适用于各种类型的取代环丙基醇和磺酰胺类化合物,例如芳环上带有吸电子基团、给电子基团和具有位阻效应的基团的环丙基醇,含有吸电子以及给电子基团的磺酰胺类化合物.相对便宜、容易获得的Tf OH是一种有效的替代金属催化合成四氢吡咯的试剂.     

含柔性链段的苯并二啞唑类聚合物合成与表征

通过溶液缩聚反应,合成了一系列含有刚性苯并啞唑环和柔性脂肪链的刚、柔间隔聚合物.通过FT-IR1、H-NMR和TGA等方法对聚合物化学结构和热失重行为进行了表征.发现聚合物分子链中出现了微量未闭环结构,热分解温度有所降低.聚合物溶液的紫外吸收光谱的最大吸收从PBO的429 nm蓝移到PBOC7的291 nm,同时荧光Stokes位移增大.     

氟原子在药物分子设计中的应用

含氟药物在临床治疗药物中占有相当比重.将氟原子或含氟基团引入到小分子药物中,是药物化学结构改造的重要研究策略之一.综述了氟原子在药物分子设计中的应用,氟原子或含氟基团的引入可以调节药物小分子的物理化学特性,改变小分子的药代动力学性质,提高药物的生物利用度;通过影响化合物的构象,增强配体与靶标蛋白的相互结合能力以及对其它靶标蛋白的选择性;通过阻断易代谢位点进而提高药物代谢稳定性等.     

An Insight into Antihyperlipidemic Effects of Polysaccharides from Natural Resources

Hyperlipidemia is a chronic metabolic disease caused by the abnormal metabolism of lipoproteins in the human body. Its main hazard is to accelerate systemic atherosclerosis, which causes cerebrovascular diseases such as coronary heart disease and thrombosis. At the same time, although the current hypolipidemic drugs have a certain therapeutic effect, they have side effects such as liver damage and digestive tract discomfort. Many kinds of polysaccharides from natural resources possess therapeutic effects on hyperlipidemia but still lack a comprehensive understanding. In this paper, the research progress of natural polysaccharides on reducing blood lipids in recent years is reviewed. The pharmacological mechanisms and targets of natural polysaccharides are mainly introduced. The relationship between structure and hypolipidemic activity is also discussed in detail. This review will help to understand the value of polysaccharides in lowering blood lipids and provide guidance for the development and clinical application of new hypolipidemic drugs.     

Drugs That Changed Society: History and Current Status of the Early Antibiotics: Salvarsan,Sulfonamides, and β-Lactams

The appearance of antibiotic drugs revolutionized the possibilities for treatment of diseases with high mortality such as pneumonia, sepsis, plaque, diphtheria, tetanus, typhoid fever, and tuberculosis. Today fewer than 1% of mortalities in high income countries are caused by diseases caused by bacteria. However, it should be recalled that the antibiotics were introduced in parallel with sanitation including sewerage, piped drinking water, high standard of living and improved understanding of the connection between food and health. Development of salvarsan, sulfonamides, and β-lactams into efficient drugs is described. The effects on life expectancy and life quality of these new drugs are indicated.     

血脑屏障通透性增效方法的研究进展

血脑屏障作为脑部的屏障系统,具有较强的保护作用,维持着中枢神经系统的内环境的稳定,同时也阻止药物进入脑部治疗中枢神经系统疾病。多年来,在提高血脑屏障通透性的研究方面有了很大进展,让药物靶向入脑,为治疗中枢神经系统疾病提供了很大的帮助。本文系统介绍血脑屏障的结构,其中主要介绍产生血脑屏障的解剖和功能结构,并对提高其通透性的增效方法和机制进行了概括,主要从物理、化学、生物学和纳米给药载体等方面阐述了提高血脑屏障透过方式,并简要介绍了一些具体药物的输送的应用。     

脂质纳米颗粒的制备及在基因治疗中的应用

基因治疗已经成为人类治疗疾病的一种重要手段.然而,为了将基因药物用于临床,需要更加复杂的递送系统.脂质纳米颗粒(LNPs)系统是目前领先的非病毒递送系统,在治疗诊断学方面取得了许多令人鼓舞的进展,其具有实现基因药物临床治疗应用的潜力.由于LNPs纳米尺寸的优势及类脂化合物的生物相容性和生物降解性,LNPs能够克服阻碍基...     

Hereditary diseases--causes, cures, and problems

The nature of the biochemical abnormalities in over a hundred inherited diseases of humans is now convincingly established. This impressive achievement has provided numerous practical benefits, amongst which are: 1. accurate methods for the diagnosis of patients with these diseases; 2. identification of symptom-free heterozygous carriers of the defective genes; and 3. procedures for the antenatal detection of a large number of these disorders in fetuses. It is anticipated that equally impressive advances will be made in the future regarding the therapy for patients with these diseases who escape prenatal detection, or in cases when an affected fetus is identified but is carried to term in compliance with the decision of the parents. The current concepts regarding the therapy of heritable metabolic diseases are outlined and potential innovations for future corrective procedures are indicated in this report.     

New Promising Therapeutic Avenues of Curcumin in Brain Diseases

Curcumin, the dietary polyphenol isolated from Curcuma longa (turmeric), is commonly used as an herb and spice worldwide. Because of its bio-pharmacological effects curcumin is also called “spice of life”, in fact it is recognized that curcumin possesses important proprieties such as anti-oxidant, anti-inflammatory, anti-microbial, antiproliferative, anti-tumoral, and anti-aging. Neurodegenerative diseases such as Alzheimer’s Diseases, Parkinson’s Diseases, and Multiple Sclerosis are a group of diseases characterized by a progressive loss of brain structure and function due to neuronal death; at present there is no effective treatment to cure these diseases. The protective effect of curcumin against some neurodegenerative diseases has been proven by in vivo and in vitro studies. The current review highlights the latest findings on the neuroprotective effects of curcumin, its bioavailability, its mechanism of action and its possible application for the prevention or treatment of neurodegenerative disorders.     

Combined nanosuspensions from two natural active ingredients for cancer therapy with reduced side effects

Tumor drug resistance and systemic side effects of chemotherapeutic drugs are the main reasons for the failure of cancer treatment. In recent years, it was found that some natural active ingredients can reverse MDR and regulate body immunity to enhance the efficacy and reduce toxicity of chemotherapeutic drugs. In this paper, a new nanosuspensions, HCPT and QUR hybrid nanosuspensions (HQ-NPs), was prepared by the microprecipitation-high pressure homogenization method to reverse tumor drug resistance, reduce toxicity, and increase therapeutic efficacy. The in vitro investigation results showed that HQ-NPs had a unique shape (particle size was about 216.3 ± 5.9 nm), changed crystalline, and different dissolution rates compared with HCPT-NPs and QUR-NPs, which is attributed to the strong intermolecular forces between HCPT and QUR as indicated by the results of the molecule dock. It was verified that the HQ-NPs could double the retention of HCPT in cells and enhance the cytotoxicity to A549/PTX cells in vitro tests compared with HCPT-NPs. We also found that HQ-NPs can significantly enhance the accumulation of HCPT in tumor sites, improve the antitumor activity of HCPT, and protect the immune organs and other normal tissues (P < 0.01), compared with HCPT-NPs. Therefore, hybrid nanosuspensions can offer promising potential as the drug delivery system for HCPT and QUR to increase the therapeutic efficacy and reduce the toxicity of HCPT.     

Development and application of nano-flavor-drug carriers in neurodegenerative diseases

Nano-drug carriers such as liposomes, polymer micelles, and polymer nanoparticles are used for neurodegenerative diseases, which can help drug pass the blood-brain barrier easily, and improve the therapeutic effect.